光流干扰对多发性硬化症患者的平衡影响
Olivia S Elie1, Jason R Franz2, Brian P Selgrade1
1Department of Sports Medicine and Human Performance, Westfield State University, Westfield, MA, USA.
Journal of applied biomechanics
|November 14, 2023
概括
光流干扰揭示了多发性硬化症 (PwMS) 患者的平衡缺陷. PwMS显示干部摆动变化增加,这表明基于视觉的平衡挑战可以选多发性硬化症相关的平衡问题.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 康复科学 康复科学 康复科学
背景情况:
- 多发性硬化症 (MS) 是一种神经退行性疾病,即使在早期也会影响平衡.
- 患有多发性硬化症 (PwMS) 的人可能更依赖视觉输入来维持平衡.
- 光学流动干扰提供了一种潜在的方法来选PwMS中的余额赤字.
研究的目的:
- 调查光流干扰对PwMS静止平衡的影响.
- 为了比较PwMS的平衡反应与健康对照在扰乱条件下的平衡反应.
- 为了确定前后 (A-P) 干扰是否比PwMS中中侧 (M-L) 干扰更破坏平衡.
主要方法:
- 13个PwMS和13个年龄和性别匹配的对照参与了这项研究.
- 参与者处于三个条件下:没有扰动,M-L扰动和A-P扰动.
- 测量了车的摆动和压力中心 (COP) 的变化,以评估平衡.
主要成果:
- 与对照组相比,PwMS在A-P扰动期间表现出明显更大的A-P干摇摆变化.
- 两种M-L和A-P扰动都增加了两组的干部摇摆和COP变化.
- 干部摇摆变化表明PwMS比对照对光流干扰更容易受到影响.
结论:
- 光学流动干扰可以有效地突出PwMS中的平衡损害.
- 这种方法作为一种敏感的查工具,有望用于早期检测多发性硬化症中平衡缺陷.
- 虽然这两种扰动类型都影响了平衡,但A-P扰动对PwMS的干部摆动产生了更大的影响.
更多相关视频
相关概念视频
Disorders of the Female Reproductive System
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...


